Skye Bioscience Inc Quick Ratio (SKYE) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Skye Bioscience Inc   (NASDAQ: SKYE)

Skye Bioscience Inc 's Quick Ratio

SKYE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 1.64 below Skye Bioscience Inc average.

Within Major Pharmaceutical Preparations industry 303 other companies have achieved higher Quick Ratio than Skye Bioscience Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 731 to 1255.

Explain Quick Ratio?
How much Cash & cash equivalents SKYE´s has?
What are SKYE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SKYE Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 95.6 % 89.11 % 123.21 % -41.97 % -66.33 %
Y / Y Cash & cash equivalent Change -71.11 % -62.38 % -53.84 % -41.6 % -35.92 %
Quick Ratio MRQ 1.64 3.14 4.22 5.85 11.13
SKYE's Total Ranking # 1255 # 731 # 0 # 428 # 277
Seq. Current Liabilities Change 26.8 % -1.94 % 0.68 % 56.25 % 22.6 %
Seq. Cash & cash equivalent Change -33.53 % -27.12 % -27.32 % -17.96 % -13.44 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 304
Healthcare Sector # 519
Overall Market # 1255


Quick Ratio Statistics
High Average Low
20.4 2.97 0.03
(Sep 30 2024)  




Financial Statements
Skye Bioscience Inc 's Current Liabilities $ 10 Millions Visit SKYE's Balance sheet
Skye Bioscience Inc 's Cash & cash equivalent $ 17 Millions Visit SKYE's Balance sheet
Source of SKYE's Sales Visit SKYE's Sales by Geography


Cumulative Skye Bioscience Inc 's Quick Ratio

SKYE's Quick Ratio for the trailling 12 Months

SKYE Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 27.26 % -20.95 % -44.66 % -59.52 % -43.06 %
Y / Y Cash & cash equivalent TTM Growth -55.89 % -47.32 % -20.57 % 32.73 % 161.53 %
Quick Ratio TTM 3.59 5.59 8.03 11.64 10.36
Total Ranking TTM # 2966 # 2759 # 0 # 2514 # 2782
Seq. Current Liabilities TTM Growth 16.84 % 14.68 % 21.27 % -21.68 % -27.43 %
Seq. Cash & cash equivalent TTM Growth -24.94 % -20.18 % -16.3 % -12.05 % -10.36 %

Quick ratio ranking by company, industry and sector >> Back to SKYE Financial Strength Comparisons >> Go to Compare SKYE Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2026 to $10.40 millions, cumulative Quick Ratio decreased to 3.59 below the Skye Bioscience Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 398 other companies have achieved higher Quick Ratio than Skye Bioscience Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2759 to 2966.

Explain Quick Ratio?
How much Cash & cash equivalents SKYE´s has?
What are SKYE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 399
Healthcare Sector # 806
Within the Market # 2966


trailing twelve months Quick Ratio Statistics
High Average Low
10.71 3.64 0.13
(Jun 30 2025)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Septerna Inc   4.44 $ 347.401  Millions$ 78.165  Millions
Gain Therapeutics inc  4.39 $ 16.539  Millions$ 3.770  Millions
Atossa Therapeutics Inc   4.27 $ 31.828  Millions$ 7.457  Millions
Zevra Therapeutics Inc   4.27 $ 200.616  Millions$ 47.028  Millions
Larimar Therapeutics Inc   4.20 $ 200.385  Millions$ 47.757  Millions
Bio Green Med Solution Inc   4.19 $ 3.339  Millions$ 0.796  Millions
Syndax Pharmaceuticals Inc   4.19 $ 361.239  Millions$ 86.174  Millions
Reshape Lifesciences Inc  4.10 $ 8.796  Millions$ 2.144  Millions
Marker Therapeutics inc   4.10 $ 14.916  Millions$ 3.638  Millions
Ars Pharmaceuticals Inc   4.05 $ 200.969  Millions$ 49.612  Millions
Palatin Technologies Inc   4.01 $ 10.159  Millions$ 2.536  Millions
Entrada Therapeutics Inc   3.98 $ 76.444  Millions$ 19.195  Millions
Lisata Therapeutics Inc   3.94 $ 13.060  Millions$ 3.315  Millions
Arcus Biosciences Inc   3.93 $ 822.000  Millions$ 209.000  Millions
Maravai Lifesciences Holdings Inc   3.89 $ 165.922  Millions$ 42.622  Millions
Serina Therapeutics Inc   3.87 $ 24.526  Millions$ 6.340  Millions
Aclaris Therapeutics Inc   3.85 $ 105.416  Millions$ 27.370  Millions
Genelux Corporation  3.77 $ 26.209  Millions$ 6.956  Millions
Scynexis Inc   3.73 $ 59.263  Millions$ 15.900  Millions
Gt Biopharma Inc   3.69 $ 8.923  Millions$ 2.416  Millions
Pulmatrix Inc   3.67 $ 3.324  Millions$ 0.905  Millions
Acurx Pharmaceuticals inc   3.66 $ 9.255  Millions$ 2.527  Millions
Longeveron Inc   3.63 $ 15.758  Millions$ 4.345  Millions
Reviva Pharmaceuticals Holdings Inc   3.63 $ 22.190  Millions$ 6.119  Millions
Xilio Therapeutics Inc   3.62 $ 150.333  Millions$ 41.576  Millions
United Therapeutics Corporation  3.59 $ 2,153.700  Millions$ 599.100  Millions
Vistagen Therapeutics Inc   3.55 $ 45.403  Millions$ 12.795  Millions
Hepion Pharmaceuticals Inc   3.54 $ 2.603  Millions$ 0.736  Millions
Enanta Pharmaceuticals Inc  3.53 $ 163.774  Millions$ 46.442  Millions
Rani Therapeutics Holdings Inc   3.50 $ 43.403  Millions$ 12.395  Millions

Date modified: 2026-09-12T06:12:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.